Author:
Fiordalisi James J.,Der Channing J.,Cox Adrienne D.
Reference131 articles.
1. Ahmad, T. and Eisen, T. (2004). 43-9006 in renal cell carcinoma. Clin Cancer Res. 10, 6388S-6392S.
2. Ahmad, T., Marais, R., Pyle, L., James, M., Schwartz, B., Gore, M., Eisen, T. (2004). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:7506.
3. Aiyagari, A.L., Taylor, B.R., Aurora, V., Young, S.G. and Shannon, K.M. (2003). Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood. 101, 2250-2252.
4. Ashar, H.R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., Bishop, W.R. and Kirschmeier, P. (2000). Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 275, 30451-30457.
5. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C.G., Schwartz, B. and Piccart, M. (2005). Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 92, 1855-1861.